

Emily Blyth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6151918/publications.pdf>

Version: 2024-02-01

75
papers

1,794
citations

304602

22
h-index

289141

40
g-index

80
all docs

80
docs citations

80
times ranked

2341
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunoprofiling reveals cell subsets associated with the trajectory of cytomegalovirus reactivation post stem cell transplantation. <i>Nature Communications</i> , 2022, 13, 2603.	5.8	8
2	Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant. <i>American Journal of Hematology</i> , 2022, , .	2.0	1
3	Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. <i>Blood Advances</i> , 2022, 6, 4949-4966.	2.5	16
4	Successful treatment of CMV, EBV, and adenovirus tissue infection following HLA-mismatched allogeneic stem cell transplant using infusion of third-party T cells from multiple donors in addition to antivirals, rituximab, and surgery. <i>Transplant Infectious Disease</i> , 2021, 23, e13528.	0.7	6
5	Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant. <i>Clinical and Translational Immunology</i> , 2021, 10, e1249.	1.7	25
6	Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity. <i>Journal of Virology</i> , 2021, 95, .	1.5	48
7	Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. <i>Blood</i> , 2021, 138, 1504-1509.	0.6	86
8	Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. <i>Blood</i> , 2021, 138, 1391-1405.	0.6	87
9	Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells. <i>American Journal of Transplantation</i> , 2021, 21, 3465-3471.	2.6	13
10	Cytomegalovirus Infections in Children with Primary and Secondary Immune Deficiencies. <i>Viruses</i> , 2021, 13, 2001.	1.5	13
11	Beyond antivirals: virus-specific T-cell immunotherapy for BK virus haemorrhagic cystitis and JC virus progressive multifocal leukoencephalopathy. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 627-634.	1.3	6
12	Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control. <i>Blood</i> , 2021, 138, 255-255.	0.6	0
13	treekoR: identifying cellular-to-phenotype associations by elucidating hierarchical relationships in high-dimensional cytometry data. <i>Genome Biology</i> , 2021, 22, 324.	3.8	3
14	A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). <i>Blood</i> , 2021, 138, 2350-2350.	0.6	4
15	Pre- and post-bone marrow harvest anaemia is associated with lower CD34+ stem cell collection, high harvest volume and female gender. <i>Internal Medicine Journal</i> , 2020, 50, 299-306.	0.5	1
16	Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection. <i>Clinical and Translational Immunology</i> , 2020, 9, e1200.	1.7	8
17	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489.	0.8	107
18	Whole-Genome Approach to Assessing Human Cytomegalovirus Dynamics in Transplant Patients Undergoing Antiviral Therapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 267.	1.8	17

#	ARTICLE	IF	CITATIONS
19	Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells. <i>Clinical and Translational Immunology</i> , 2020, 9, e1149.	1.7	18
20	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1868-1875.	2.0	8
21	Profiling the Blood Compartment of Hematopoietic Stem Cell Transplant Patients During Human Cytomegalovirus Reactivation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 607470.	1.8	4
22	Single cell analysis reveals human cytomegalovirus drives latently infected cells towards an anergic-like monocyte state. <i>ELife</i> , 2020, 9, .	2.8	46
23	Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial). <i>Blood</i> , 2020, 136, 38-38.	0.6	0
24	Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Frontiers in Microbiology</i> , 2019, 10, 1186.	1.5	105
25	Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 247-260.	1.2	8
26	Restriction of Human Cytomegalovirus Infection by Galectin-9. <i>Journal of Virology</i> , 2019, 93, .	1.5	18
27	Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial). <i>Blood</i> , 2019, 134, 251-251.	0.6	3
28	Ultra-Sensitive Droplet Digital PCR for the Assessment of Microchimerism in Cellular Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1069-1078.	2.0	36
29	Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 71-77.	2.0	13
30	Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2433-2442.	2.0	50
31	Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 1672.	2.2	46
32	Rescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a single-centre case series. <i>Internal Medicine Journal</i> , 2018, 48, 988-991.	0.5	5
33	Co-Administration of 3rdparty Partially HLA Matched Cytomegalovirus Specific T Cells with Initial Antiviral Pharmacotherapy for Post-Transplant Viral Reactivation. <i>Blood</i> , 2018, 132, 2051-2051.	0.6	0
34	Unique case involving chromosomes 3 and 11 in myelodysplastic syndromes (MDS) confirmed by microarray studies. <i>Pathology</i> , 2017, 49, S106.	0.3	0
35	Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant. <i>Cytotherapy</i> , 2017, 19, 1284-1301.	0.3	17
36	Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy. <i>Cytotherapy</i> , 2017, 19, 107-118.	0.3	14

#	ARTICLE	IF	CITATIONS
37	Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. <i>Blood Advances</i> , 2017, 1, 2193-2205.	2.5	115
38	Third-Party Virus-Specific T Cells (VST) Are Efficacious in the Treatment of Refractory Infection Post-HSCT, However Other Cell-Mediated Immune Deficiencies Appear to Persist. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S147.	2.0	1
39	Multi-Pathogen Cytotoxic T-Lymphocytes to Enhance Immunity Post-Allogeneic Stem Cell Transplantation (HSCT). <i>Cytotherapy</i> , 2016, 18, S14.	0.3	0
40	CMV-specific immune reconstitution following allogeneic stem cell transplantation. <i>Virulence</i> , 2016, 7, 967-980.	1.8	45
41	Infusion of Unrelated-Donor Partially HLA-Matched Cells Results in Detectable Microchimerism in Patients with Acute Myeloid Leukemia: Early Post-Infusion Reactions Are Common but Self-Limiting. <i>Blood</i> , 2016, 128, 3405-3405.	0.6	1
42	449. Multipathogen-Specific T Cells for Immune Reconstitution – A Decade of Manufacturing Development and Clinical Use. <i>Molecular Therapy</i> , 2015, 23, S178.	3.7	0
43	Moving towards pathogen-specific T cells post-stem cell transplant as standard of care. <i>ISBT Science Series</i> , 2015, 10, 349-356.	1.1	0
44	Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 941-944.	2.0	48
45	Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. <i>Cytotherapy</i> , 2015, 17, 1251-1267.	0.3	75
46	Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1641-1645.	2.0	38
47	Adoptive T Cell Immunotherapy for Treatment of Ganciclovir-Resistant Cytomegalovirus Disease in a Renal Transplant Recipient. <i>American Journal of Transplantation</i> , 2015, 15, 827-832.	2.6	54
48	Infusion of third-party partially HLA-matched virus-specific T cells to treat refractory viral infections. <i>Cytotherapy</i> , 2015, 17, S8-S9.	0.3	0
49	Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2015, 17, 1406-1420.	0.3	53
50	A fatal case of acute HHV-6 myocarditis following allogeneic haemopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2015, 72, 82-84.	1.6	5
51	Third-Party Donor Virus-Specific T Cells Are Efficacious in the Treatment of Refractory Viral Infection Following Allogeneic HSCT, but May Not Persist Post-Infusion. <i>Blood</i> , 2015, 126, 623-623.	0.6	6
52	Therapeutic Infusion of Partially HLA-Matched Third-Party Virus-Specific T Cells in HSCT Patients with Refractory Viral Infection. <i>Blood</i> , 2014, 124, 3835-3835.	0.6	0
53	Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factor-Mobilized Hemopoietic Progenitor Cell Products Ex Vivo and Safely Transferred to Stem Cell Transplantation Recipients to Facilitate Immune Reconstitution. <i>Biology of Blood and Marrow Transplantation</i> . 2013. 19. 725-734.	2.0	34
54	Prophylactic infusion of multi-virus specific T cells for management of viral reactivation and infection in patients post allogeneic hematopoietic stem cell transplantation (HSCT). <i>Cytotherapy</i> , 2013, 15, S10.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Establishment of an australian bank of third party antiviral cytotoxic T lymphocytes (CTL). Cytotherapy, 2013, 15, S38.	0.3	0
56	Reduced Intensity Transplants Using G-CSF-Mobilized Hemopoietic Cells From Haploidentical Related Donors. Biology of Blood and Marrow Transplantation, 2013, 19, S283.	2.0	2
57	Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood, 2013, 121, 3745-3758.	0.6	219
58	Prophylactic Infusion Of Multi-Virus Specific T Cells For Management Of Viral Reactivation and Infection In Patients Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2013, 122, 4498-4498.	0.6	0
59	In vitro generation of influenza-specific polyfunctional CD4+ T cells suitable for adoptive immunotherapy. Cytotherapy, 2012, 14, 182-193.	0.3	16
60	Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients. Cytotherapy, 2012, 14, 724-732.	0.3	24
61	Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy, 2012, 14, 1119-1130.	0.3	29
62	Cytotoxic T Cells Specific for Adenovirus, BKV, CMV, EBV and VZV Produced for Clinical Use in Immune Reconstitution Post Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, S211-S212.	2.0	0
63	Cytomegalovirus (CMV) pp65 Specific T Cells Expanded From Mobilised Peripheral Blood Stem Cell (PBSC) Collections for Prophylactic Adoptive Immunotherapy. Biology of Blood and Marrow Transplantation, 2011, 17, S212.	2.0	0
64	BK Virus Specific T Cells Expanded Ex Vivo for Use in Cellular Therapy Show Multiple Antigen Specificity and Polyfunctional Th1 Responses. Biology of Blood and Marrow Transplantation, 2011, 17, S214.	2.0	0
65	The Generation of Clinical Grade Aspergillus Fumigatus (AF) Specific Immune Cells for Adoptive Immunotherapy. Biology of Blood and Marrow Transplantation, 2011, 17, S215.	2.0	0
66	BK Virus-Specific T Cells for Use in Cellular Therapy Show Specificity to Multiple Antigens and Polyfunctional Cytokine Responses. Transplantation, 2011, 92, 1077-1084.	0.5	61
67	In Vitro Generation of Influenza-Virus Specific T Cells for Adoptive Immunotherapy,. Blood, 2011, 118, 4040-4040.	0.6	0
68	Cytotoxic T Cells Specific for Adenovirus, BK Virus, Cytomegalovirus, Epstein Barr Virus and Varicella Zoster Virus Produced for Clinical Use In Immune Reconstitution Post Allogeneic Stem Cell Transplantation. Blood, 2010, 116, 830-830.	0.6	0
69	Epstein-Barr Virus Specific Cytotoxic T Cells for Clinical Use in Immune Reconstitution Post Haemopoietic Stem Cell Transplant.. Blood, 2009, 114, 2435-2435.	0.6	0
70	BK Virus Specific Cytotoxic T Cells Expanded for Clinical Use Exhibit Multiple Cytokine Functions and Individual Variation in Antigen Specificity.. Blood, 2009, 114, 2437-2437.	0.6	0
71	Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood, 2008, 112, 3974-3981.	0.6	108
72	Protein Z is reduced in chronic kidney disease and not elevated in patients on haemodialysis. Blood Coagulation and Fibrinolysis, 2008, 19, 23-25.	0.5	2

#	ARTICLE	IF	CITATIONS
73	CMV Specific T Cells for Adoptive Transfer Exhibit Multiple Effector Functions Associated with Protective Immunity Including the Concurrent Production of Cytokines and Cytolytic Activity. <i>Blood</i> , 2008, 112, 3481-3481.	0.6	0
74	Letters to the Editor. <i>Leukemia and Lymphoma</i> , 2006, 47, 747-775.	0.6	14
75	A novel cytogenetic abnormality in Burkitt lymphoma associated with treatment resistant disease. <i>International Journal of Laboratory Hematology</i> , 2005, 27, 328-330.	0.2	3